PL2793913T3 - Schemat dawkowania dla formulacji apolipoproteiny - Google Patents

Schemat dawkowania dla formulacji apolipoproteiny

Info

Publication number
PL2793913T3
PL2793913T3 PL12859136.9T PL12859136T PL2793913T3 PL 2793913 T3 PL2793913 T3 PL 2793913T3 PL 12859136 T PL12859136 T PL 12859136T PL 2793913 T3 PL2793913 T3 PL 2793913T3
Authority
PL
Poland
Prior art keywords
dosage schedule
apolipoprotein formulation
apolipoprotein
formulation
schedule
Prior art date
Application number
PL12859136.9T
Other languages
English (en)
Polish (pl)
Inventor
Craig RAYNER
Original Assignee
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905368A external-priority patent/AU2011905368A0/en
Application filed by Csl Limited filed Critical Csl Limited
Publication of PL2793913T3 publication Critical patent/PL2793913T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12859136.9T 2011-12-21 2012-11-02 Schemat dawkowania dla formulacji apolipoproteiny PL2793913T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011905368A AU2011905368A0 (en) 2011-12-21 Dosing regime for apolipoprotein formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Publications (1)

Publication Number Publication Date
PL2793913T3 true PL2793913T3 (pl) 2023-11-06

Family

ID=48667485

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12859136.9T PL2793913T3 (pl) 2011-12-21 2012-11-02 Schemat dawkowania dla formulacji apolipoproteiny

Country Status (16)

Country Link
US (3) US20140378376A1 (enExample)
EP (1) EP2793913B1 (enExample)
JP (2) JP6144276B2 (enExample)
KR (3) KR102766038B1 (enExample)
CN (2) CN104010646A (enExample)
AU (1) AU2012310259C1 (enExample)
BR (1) BR112014014403A8 (enExample)
CA (1) CA2857968A1 (enExample)
DK (1) DK2793913T3 (enExample)
ES (1) ES2955110T3 (enExample)
IL (1) IL233236A0 (enExample)
MX (1) MX377093B (enExample)
PL (1) PL2793913T3 (enExample)
RU (1) RU2014129505A (enExample)
SG (1) SG11201402556RA (enExample)
WO (1) WO2013090978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645037B2 (en) 2011-09-28 2017-05-09 Hunter Engineering Company Method and apparatus for wheel assembly lateral force measurement
KR102766038B1 (ko) * 2011-12-21 2025-02-12 시에스엘 리미티드 아포지질단백질 제형을 위한 용량 용법
CN116196395A (zh) 2016-11-10 2023-06-02 杰特有限公司 心肌梗塞的重构的高密度脂蛋白治疗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
CA2460787A1 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
JP2006507223A (ja) * 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
AP2006003578A0 (en) * 2003-10-20 2006-04-30 Esperion Therapeutics Inc Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes.
JP2009505652A (ja) * 2005-08-26 2009-02-12 セレニス セラピューティクス ホールディング エスア 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法
US20090297577A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of Apolipoproteins and Their Derivatives
KR102766038B1 (ko) * 2011-12-21 2025-02-12 시에스엘 리미티드 아포지질단백질 제형을 위한 용량 용법

Also Published As

Publication number Publication date
JP6144276B2 (ja) 2017-06-07
EP2793913A1 (en) 2014-10-29
KR20190084334A (ko) 2019-07-16
KR102766038B1 (ko) 2025-02-12
JP2017128586A (ja) 2017-07-27
EP2793913B1 (en) 2023-06-21
US20140378376A1 (en) 2014-12-25
HK1199813A1 (en) 2015-07-24
RU2014129505A (ru) 2016-02-10
CA2857968A1 (en) 2013-06-27
AU2012310259A1 (en) 2013-07-11
KR20140107536A (ko) 2014-09-04
MX2014006589A (es) 2014-10-17
CN113398245A (zh) 2021-09-17
DK2793913T3 (da) 2023-08-21
SG11201402556RA (en) 2014-10-30
ES2955110T3 (es) 2023-11-28
US20240216467A1 (en) 2024-07-04
CN104010646A (zh) 2014-08-27
AU2012310259B2 (en) 2015-07-30
RU2017129700A (ru) 2019-02-04
EP2793913A4 (en) 2015-06-10
AU2012310259C1 (en) 2016-07-14
RU2017129700A3 (enExample) 2021-02-26
IL233236A0 (en) 2014-08-31
MX377093B (es) 2025-03-07
BR112014014403A2 (pt) 2017-06-13
JP2015500840A (ja) 2015-01-08
NZ624558A (en) 2015-08-28
WO2013090978A1 (en) 2013-06-27
US20160175392A1 (en) 2016-06-23
BR112014014403A8 (pt) 2021-03-09
KR20200037879A (ko) 2020-04-09

Similar Documents

Publication Publication Date Title
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
DK2827710T3 (da) Doseringsskema for echinocandin-klasse-forbindelser
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
LT2872491T (lt) Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
BR112013014361A2 (pt) forma de dosagem
DK2706982T4 (da) Intranasale farmaceutiske dosisformer omfattende naloxon
DK3278792T3 (da) Lægemiddelformulering med forsinket udløsning
PL3156056T3 (pl) Kompozycje farmaceutyczne zawierające estry sorbitanu
DK2701773T3 (da) Dosisstyredele til injektionssprøjte
CO6930367A2 (es) Composiciones farmaceúticas
DK2525798T3 (da) Anæstetisk formulering
EP2673344A4 (en) STABLE BIO OIL
EP2688690A4 (en) ACTIVE ELECTROADHESION CLEANING
BR112013025761A2 (pt) inibidores de hsp90
CO6940426A2 (es) Formulaciones farmacéuticas
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
BR112014000015A2 (pt) formulação
DK2613888T3 (da) Doseringsanordning
EP2552212A4 (en) IMPROVED FORMULATION
CO6870048A2 (es) Formulación herbicida mejorada
EP2717058A4 (en) Autoanalyzer
EP2531023A4 (en) IMPROVED FORMULATION
BR112013000356A2 (pt) formulação farmacêutica injetável de malfalano
DK3335753T3 (da) Dispenser med dosistæller